Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review

Abstract Although the biological properties of mesenchymal stem cells (MSC) are well-characterized in vitro, MSC clinical application is still far away to be achieved, mainly due to the need of xenogeneic substances for cell expansion, such as fetal bovine serum (FBS). FBS presents risks regarding pathogens transmissions and internalization of animal’s proteins, which can unleash antigenic responses in patients after MSC implantation. A wide range of venous blood derivatives (VBD) has been reported as FBS substitutes showing promising results. Thus, the aim of this study was to conduct a systematic scoping review to analyze whether VBD are effective FBS substitutes for MSC ex vivo expansion. The search was performed in SciVerse ScopusTM, PubMed, Web of ScienceTM, BIREME, Cochrane library up to January 2016. The keywords were selected using MeSH and entry terms. Two independent reviewers scrutinized the records obtained considering specific inclusion criteria. The included studies were evaluated in accordance with a modified Arksey and O’ Malley’s framework. From 184 found studies, 90 were included. Bone marrow mesenchymal stem cells (BMMSC) were presented in most of these studies. Overall, VBD allowed for either, maintenance of MCS’s fibroblast-like morphology, high proliferation, high colony-formation ability and maintenance of multipotency. Besides. MSC expanded in VBD supplements presented higher mitogen activity than FBS. VBD seems to be excellent xeno-free serum for ex vivo expansion of mesenchymal stem cells. However, an accentuated heterogeneity was observed between the carried out protocols for VBD isolation did not allowing for direct comparisons between the included studies.

Saved in:
Bibliographic Details
Main Authors: Chisini,Luiz A., Conde,Marcus C.M., Grazioli,Guillermo, Martin,Alissa S. San, Carvalho,Rodrigo Varella de, Nör,Jacques E., Demarco,Flávio F.
Format: Digital revista
Language:English
Published: Fundação Odontológica de Ribeirão Preto 2017
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-64402017000600657
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0103-64402017000600657
record_format ojs
spelling oai:scielo:S0103-644020170006006572017-11-30Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping ReviewChisini,Luiz A.Conde,Marcus C.M.Grazioli,GuillermoMartin,Alissa S. SanCarvalho,Rodrigo Varella deNör,Jacques E.Demarco,Flávio F. human serum mesenchymal stem cells platelet venous blood derivatives xeno-free Abstract Although the biological properties of mesenchymal stem cells (MSC) are well-characterized in vitro, MSC clinical application is still far away to be achieved, mainly due to the need of xenogeneic substances for cell expansion, such as fetal bovine serum (FBS). FBS presents risks regarding pathogens transmissions and internalization of animal’s proteins, which can unleash antigenic responses in patients after MSC implantation. A wide range of venous blood derivatives (VBD) has been reported as FBS substitutes showing promising results. Thus, the aim of this study was to conduct a systematic scoping review to analyze whether VBD are effective FBS substitutes for MSC ex vivo expansion. The search was performed in SciVerse ScopusTM, PubMed, Web of ScienceTM, BIREME, Cochrane library up to January 2016. The keywords were selected using MeSH and entry terms. Two independent reviewers scrutinized the records obtained considering specific inclusion criteria. The included studies were evaluated in accordance with a modified Arksey and O’ Malley’s framework. From 184 found studies, 90 were included. Bone marrow mesenchymal stem cells (BMMSC) were presented in most of these studies. Overall, VBD allowed for either, maintenance of MCS’s fibroblast-like morphology, high proliferation, high colony-formation ability and maintenance of multipotency. Besides. MSC expanded in VBD supplements presented higher mitogen activity than FBS. VBD seems to be excellent xeno-free serum for ex vivo expansion of mesenchymal stem cells. However, an accentuated heterogeneity was observed between the carried out protocols for VBD isolation did not allowing for direct comparisons between the included studies.info:eu-repo/semantics/openAccessFundação Odontológica de Ribeirão PretoBrazilian Dental Journal v.28 n.6 20172017-12-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-64402017000600657en10.1590/0103-6440201701646
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Chisini,Luiz A.
Conde,Marcus C.M.
Grazioli,Guillermo
Martin,Alissa S. San
Carvalho,Rodrigo Varella de
Nör,Jacques E.
Demarco,Flávio F.
spellingShingle Chisini,Luiz A.
Conde,Marcus C.M.
Grazioli,Guillermo
Martin,Alissa S. San
Carvalho,Rodrigo Varella de
Nör,Jacques E.
Demarco,Flávio F.
Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review
author_facet Chisini,Luiz A.
Conde,Marcus C.M.
Grazioli,Guillermo
Martin,Alissa S. San
Carvalho,Rodrigo Varella de
Nör,Jacques E.
Demarco,Flávio F.
author_sort Chisini,Luiz A.
title Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review
title_short Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review
title_full Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review
title_fullStr Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review
title_full_unstemmed Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review
title_sort venous blood derivatives as fbs-substitutes for mesenchymal stem cells: a systematic scoping review
description Abstract Although the biological properties of mesenchymal stem cells (MSC) are well-characterized in vitro, MSC clinical application is still far away to be achieved, mainly due to the need of xenogeneic substances for cell expansion, such as fetal bovine serum (FBS). FBS presents risks regarding pathogens transmissions and internalization of animal’s proteins, which can unleash antigenic responses in patients after MSC implantation. A wide range of venous blood derivatives (VBD) has been reported as FBS substitutes showing promising results. Thus, the aim of this study was to conduct a systematic scoping review to analyze whether VBD are effective FBS substitutes for MSC ex vivo expansion. The search was performed in SciVerse ScopusTM, PubMed, Web of ScienceTM, BIREME, Cochrane library up to January 2016. The keywords were selected using MeSH and entry terms. Two independent reviewers scrutinized the records obtained considering specific inclusion criteria. The included studies were evaluated in accordance with a modified Arksey and O’ Malley’s framework. From 184 found studies, 90 were included. Bone marrow mesenchymal stem cells (BMMSC) were presented in most of these studies. Overall, VBD allowed for either, maintenance of MCS’s fibroblast-like morphology, high proliferation, high colony-formation ability and maintenance of multipotency. Besides. MSC expanded in VBD supplements presented higher mitogen activity than FBS. VBD seems to be excellent xeno-free serum for ex vivo expansion of mesenchymal stem cells. However, an accentuated heterogeneity was observed between the carried out protocols for VBD isolation did not allowing for direct comparisons between the included studies.
publisher Fundação Odontológica de Ribeirão Preto
publishDate 2017
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-64402017000600657
work_keys_str_mv AT chisiniluiza venousbloodderivativesasfbssubstitutesformesenchymalstemcellsasystematicscopingreview
AT condemarcuscm venousbloodderivativesasfbssubstitutesformesenchymalstemcellsasystematicscopingreview
AT grazioliguillermo venousbloodderivativesasfbssubstitutesformesenchymalstemcellsasystematicscopingreview
AT martinalissassan venousbloodderivativesasfbssubstitutesformesenchymalstemcellsasystematicscopingreview
AT carvalhorodrigovarellade venousbloodderivativesasfbssubstitutesformesenchymalstemcellsasystematicscopingreview
AT norjacquese venousbloodderivativesasfbssubstitutesformesenchymalstemcellsasystematicscopingreview
AT demarcoflaviof venousbloodderivativesasfbssubstitutesformesenchymalstemcellsasystematicscopingreview
_version_ 1756404600118706176